https://doi.org/10.55788/fffbfaef
In this episode (20:49 min), Medicom’s correspondent covers 6 presentations from the ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2022) which was held as a hybrid event both virtually and in-person in San Francisco, CA, USA, 20-22 January 2022.
- DCF outperforms standard-of-care for locally advanced oesophageal cancer
Docetaxel plus neoadjuvant cisplatin and 5-fluorouracil (DCF) chemotherapy was superior to CF chemotherapy alone in patients with locally advanced oesophageal cancer, the primary analysis of the phase 3 JCOG1109 NExT trial showed. Moreover, the toxicity profile of the DCF combination regimen was manageable. Therefore, neoadjuvant DCF represents a new standard therapy for this patient population - DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer
The final results of the phase 2 DESTINY-Gastric01 trial showed that trastuzumab deruxtecan (T-DXd) was superior to a standard PC chemotherapy regimen in patients with HER2-positive advanced gastric or gastroesophageal cancer. Also, the updated safety data were consistent with the primary analysis of this study - HIMALAYA: Durvalumab with or without tremelimumab new first-line options for unresectable hepatocellular carcinoma
Tremelimumab plus durvalumab improved the overall survival of patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib. Also, durvalumab monotherapy was non-inferior to sorafenib. Durvalumab monotherapy and tremelimumab plus durvalumab had manageable safety profiles and may represent new first-line treatment options for this population. - KEYNOTE-590: New standard-of-care for oesophageal cancer
Pembrolizumab plus chemotherapy showed clinically meaningful benefits compared with chemotherapy alone as first-line therapy in patients with locally advanced and metastatic oesophageal cancer. Furthermore, the longer-term follow-up data of the phase 3 KEYNOTE-590 study displayed comparable safety profiles of both treatment options. These results confirm that the pembrolizumab regimen offers a new standard of care for this population. - Nivolumab plus standard-of-care does not meet primary endpoint for colorectal cancer
In the phase 2/3 CheckMate 9X8 trial, nivolumab plus standard-of-care did not significantly improve progression-free survival compared with standard-of-care alone in the first-line treatment of patients with metastatic colorectal cancer (mCRC). However, the results numerically favoured patients receiving additional nivolumab. Moreover, patients with CMS1 and CMS3 molecular subtypes, or CD8 levels ≥2% displayed benefits from nivolumab, exploratory analyses revealed [1]. - Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma
Etoposide and irinotecan showed equal efficacy in a head-to-head study among patients with advanced neuroendocrine carcinoma (NEC) of the digestive system [1]. Therefore, these agents both remain first-line therapeutic options for this population.
Enjoy listening!
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Pregnancy outcomes improving after treatment for high-grade cervical neoplasia Next Article
Coal mining, silica dust associated with rheumatoid arthritis in Appalachia »
« Pregnancy outcomes improving after treatment for high-grade cervical neoplasia Next Article
Coal mining, silica dust associated with rheumatoid arthritis in Appalachia »
Table of Contents: ASCO GI 2022
Featured articles
Oesophageal and Gastric Cancer
EMR versus ESD in oesophageal cancer
Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer
AK104 plus chemotherapy promising first-line option for gastric cancer
DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer
The emerging role of AI in gastroesophageal cancer
DCF outperforms standard-of-care for locally advanced oesophageal cancer
Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome
Updates on pembrolizumab for oesophageal and gastric cancer
Anal and Colorectal Cancer
NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC
Dostarlimab may offer an alternative for dMMR rectal cancer
DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC
Key updates in colorectal cancer screening
Impact of COVID-19 on screening for colorectal cancer
Nivolumab plus standard-of-care does not meet primary endpoint for mCRC
No benefit of additional oxaliplatin in elderly patients with mCRC
Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled
Long-course chemoradiation versus short-course radiotherapy in rectal cancer
Analysis of metastasectomy in CRC reveals benefits and disparities
EPOCH trial: Subgroup analyses and additional endpoints for TARE plus chemo
Hepatobiliary Cancer
Adjuvant S-1 therapy superior to observation in resected biliary tract cancer
Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma
TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer
HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC
LAUNCH: TACE plus lenvatinib efficacious in advanced HCC
Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC
Pancreatic Cancer
Sintilimab plus FOLFIRINOX may provide benefits in metastatic pancreatic cancer
TRYbeCA-1: Eryaspase + chemotherapy does not meet primary endpoint in pancreatic cancer
Persisting disparities in pancreatic cancer care
ctDNA promising biomarker for recurrence of pancreatic cancer
Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma
Related Articles
August 5, 2022
Novel treatment option for KRAS wildtype pancreatic cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com